Trial Profile

A phase II Clinical Trial on the use of ARA 290 for the treatment of Diabetic Macular Oedema

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cibinetide (Primary)
Indications Diabetic macular oedema
Focus Proof of concept; Therapeutic Use
Acronyms ARA290DMO

Most Recent Events

21 Jul 2020 Results published in the Journal of Clinical Medicine
20 Jul 2020 According to an Araim Pharmaceuticals media release, Dr. Noemi Lois is the lead investigator of this study.
20 Jul 2020 Results (n=9) presented in an Araim Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com